Yearly and Twice Yearly Pharmacotherapy in Postmenopausal Osteoporosis

Tandon, Vishal R.; Mir, Shakeel Ahmad; Singh, Zorawar; Sharma, Rajesh
January 2009
JK Science;Jan-Mar2009, Vol. 11 Issue 1, p47
Academic Journal
The article discusses the importance of yearly and twice yearly pharmacology in treating postmenopausal osteoporosis. It examines the efficacy of Zoledronic acid and Denosumab in treating this osteoporosis. It notes that 5 milligram of intravenous infusion of Zoledronic acid can lower bone turnover markers and vertebral marker rate, while the Denosumab can improve bone mineral density and reduce bone resorption in postmenopausal women having low bone mass. Moreover, it explores the adverse effects of these drugs.


Related Articles

  • Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis. Frampton, James E.; Perry, Caroline M. // Drugs;2008, Vol. 68 Issue 18, p2683 

    Abstract Ibandronate (ibandronic acid; Bonviva®, Boniva®), a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly intravenous formulations for intermittent administration, has been approved for the treatment of osteoporosis in postmenopausal women in the EU, the...

  • Ibandronate (Boniva) for Treatment and Prevention of Osteoporosis in Postmenopausal Women. Ference, Jonathan D.; Wilson, Stephen A. // American Family Physician;1/15/2006, Vol. 73 Issue 2, p305 

    The article provides information on the use of ibandronate (Boniva), an oral bisphosphonate approved for the treatment and prevention of osteoporosis in women who are postmenopausal. It discusses the adverse effects of the drug based on two clinical trials. It evaluates the effectiveness of...

  • ibandronate.  // Davis's Drug Guide for Nurses, 10th edition;2007, p621 

    The article presents a nursing guide for ibandronate, a drug used for treatment and prevention of postmenopausal osteoporosis. The mechanism of action of the bone resorption inhibitor is discussed. Information on its pharmacokinetics is provided. Precautionary measures and contraindications for...

  • Phenytoin.  // Reactions Weekly;2/12/2011, Issue 1338, p29 

    The article describes the case of a 6-year-old girl who developed vitamin D deficiency while receiving phenytoin for epilepsy.

  • Pamidronic acid/zoledronic acid.  // Reactions Weekly;10/10/2009, Issue 1273, p26 

    The article describes the case of a 72-year-old woman who developed avascular osteonecrosis of the jaw after treatment with pamidronic acid and zoledronic acid. The patient was found to have a prothrombin G20210A gene mutation and went through bone resection. She was given amoxicillin/clavulanic...

  • Osteoporosis drug licensed for women with high fracture risk. Traynor, Kate // American Journal of Health-System Pharmacy;7/1/2010, Vol. 67 Issue 13, p1046 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of Amgen Inc.'s denosumab injection for use in postmenopausal women who have osteoporosis and are at high risk for fracture. In Amgen's study involving 7,808 women, the twice-yearly injection of the drug reduces...

  • Brentuximab vedotin.  // Reactions Weekly;12/8/2012, Issue 1431, p12 

    The article describes the case of a 47-year-old man who experienced progressive multifocal leukoencephalopathy (PML) while receiving brentuximab vedotin for relapsed Hodgkin's lymphoma.

  • Natalizumab.  // Reactions Weekly;8/6/2011, Issue 1363, p30 

    The article describes the case of a 50-year-old woman who developed autoimmune haemolytic anaemia during treatment with natalizumab for multiple sclerosis.

  • Natalizumab.  // Reactions Weekly;8/6/2011, Issue 1363, p30 

    The article describes the case of a 40-year-old man who developed progression of primary central nervous system lymphoma while receiving natalizumab.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics